Taysha Gene Therapies, Inc. (TSHA)
SEC filings, insider trading & institutional ownership from EDGAR.
Couldn’t find the data you were looking for?
We haven’t added Taysha Gene Therapies, Inc.’s filings yet. We add companies and filings all the time.
Track TSHA and we’ll email you the moment its filings are in, free and with no account. Or create a free account to request coverage.
Latest filings
10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR
No filings are available yet.
Top holders
13F & 13D/G • latest quarter
| Holder | Filed | Value |
|---|---|---|
| GOLDMAN SACHS GROUP INC | Aug 14, 2026 | $154.68M |
| BlackRock, Inc. | Aug 7, 2026 | $140.91M |
| MORGAN STANLEY | Aug 13, 2026 | $112.28M |
| FMR LLC | Aug 13, 2026 | $90.82M |
| Vanguard Capital Management | Aug 13, 2026 | $84.98M |
TSHA's filings are public. The insight is one click away.
Scrutar's AI reads every TSHA filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.
Never miss a TSHA filing.
Get an email when TSHA files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Oct 24, 2026Source: SEC EDGAR.